← brief for 2026-09-28 · Slowing decline

Pharmacokinetics, safety, and tolerability of ceftibuten-ledaborbactam etzadroxil in participants with renal impairment.

Key takeaways

This study tested a new antibiotic mix in people with different levels of kidney damage. It checked how the body handles the drug and if it is safe. The text does not say how many people took part or how long the test ran. This helps doctors know if the drug works for people with kidney disease.

Who did this work

de Oliveira CF (De Oliveira Consulting LLC, New Hope, Pennsylvania, USA.) · Lowe K (Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA.) · Fatato P (Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA.) · Marbury T (Orlando Clinical Research Center, Orlando, Florida, USA.) · Litherland K (Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.) · Engelhardt M (Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.) · Hamed KA (Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.) · McGovern PC (McGovern ID Consulting LLC, Berwyn, Pennsylvania, USA.)

Source

Article · Europe PMC, CKD · 2026-09-28
https://doi.org/10.1128/aac.00860-26